Mineralys Therapeutics, Inc.
Reports in 15d· 2026-05-12
-16.5% · 90d
$26.99
-0.52 (-1.89%)
News
(1)April 2026
MLYS Highlights Clinical Progress in Annual Report to Shareholders
MLYSMineralys Therapeutics, Inc.
# 🧾 What This Document Is This is an **Annual Report to Shareholders (ARS)**, a document companies send to their investors each year. Think of it as the company's official "year-in-review" magazine, designed to be more readable than the dense, official 10-K filing. It typically includes a letter f
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%